Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
whole egg
- Development stage
- Unknown
- Lead developer
- Kathryn Starr
- Administration
- Oral
01
Overview
Whole egg consumption is being investigated as a nutritional intervention for the management of intermediate age-related macular degeneration (AMD). Eggs are a highly bioavailable source of the macular carotenoids lutein and zeaxanthin, which accumulate in the retina and serve as antioxidants and filters for high-energy blue light, potentially slowing the progression of AMD. This specific research, led by Kathryn Starr, involves a pilot feasibility study (EggsAMD) evaluating the effects of consuming two or four Eggland's Best eggs daily on retinal sensitivity, visual acuity, and functional outcomes in older adults.
- Brand names
- Eggland's Best
- Other names
- EggsAMD
02
Targets
HDL (High-density lipoprotein)
Beyond the preview
Go deeper on whole egg.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on whole egg.